HK Stock Market Move | CSPC PHARMA (01093) rose nearly 9%, SYS6010-022 has officially launched in China and plans to complete the enrollment of the first subject in July.

CSPC PHARMA (01093) rose nearly 9%, as of the time of writing, it rose 7.92%, to 7.22 Hong Kong dollars, with a turnover of 352 million Hong Kong dollars. On the news front, on June 26, CSPC PHARMA announced that the Phase III clinical study (study protocol number: SYS6010-022 (SYNSTAR-04)) of SYS6010, jointly developed by the group with EnLor SoBay monoclonal antibody for the treatment of driver gene-negative non-small cell lung cancer ("NSCLC"), has officially started in China. It is planned to complete the first subject enrollment by July 2026. SYS6010 is an antibody-drug conjugate (ADC) targeting the epidermal growth factor receptor (EGFR) developed by the group, which consists of a humanized anti-EGFR monoclonal antibody linked to a cleavable linker and a topoisomerase I inhibitor payload. SYS6010-022 (SYNSTAR-04) is a randomized, open-label, multicenter, Phase III clinical study aimed at evaluating the efficacy and safety of SYS6010 in combination with EnLor SoBay monoclonal antibody compared to immunotherapy plus platinum-based chemotherapy in driver gene-negative and programmed death-ligand 1 (PD-L1) -positive locally advanced or metastatic NSCLC subjects. Previously, the group received the opinion of the Center for Drug Evaluation of the National Medical Products Administration of the People's Republic of China in May 2026, agreeing to conduct this clinical trial. Currently, subject recruitment and screening work are actively underway.